Acute vasodilator testing in primary and secondary pulmonary hypertension

Wiener Klinische Wochenschrift

Volumn 113, Issue 13-14, 2001, Pages 496-503

  Schenk, P ^a   Madl, C ^a   Kramer, L ^a   Zauner, C ^a   Funk, G ^a   Lang, I ^a   Stiebellehner, L ^a   Petkov, V ^a   Vonbank, K ^a   Ziesche, R ^a   Kneussl, M ^a   Ratheiser, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Calcium channel blockers; Nitric oxide; Prostacyclin; Pulmonary hypertension; Vasodilator testing

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CATHETERIZATION; CLINICAL ARTICLE; FEMALE; GAS EXCHANGE; HEMODYNAMICS; HUMAN; MALE; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASODILATATION;

EID: 0035898174     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nomenclature and classification of pulmonary hypertension
2. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide
3. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
4. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
5. Primary pulmonary hypertension
6. Medical management of primary pulmonary hypertension
7. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
8. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension
9. Primary pulmonary hypertension
10. Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: Diminished left ventricular size and leftward ventricular septal bowing
11. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
12. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
13. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)
14. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
15. Role of pharmacologic tests in the treatment of primary pulmonary hypertension
16. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study
17. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing
18. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension
19. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange
20. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
21. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
22. Ambient nitrogen dioxide concentrations increase bronchial responsiveness in subjects with mild asthma
23. Safety guidelines for use of nitric oxide
24. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension
25. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension
26. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension
27. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension